Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1110 of 6351
-
Surgery may extend life in men with early bone metastases, major trial tests
Disease control OngoingThe aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a limited bone metastatic prostate cancer. In addition th…
Sponsor: Martini-Klinik am UKE GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered t cells take on chest cancer in new trial
Disease control OngoingThe purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood. The Investigators want to find a safe dose of these modified T cells for patients who have malignant pleural disease. They want t…
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Brain tumor surgery at recurrence: does it help?
Knowledge-focused Recruiting nowPatients with glioblastoma face a grim prognosis. Despite recent advancement in neurosurgical technology and neuro-oncology glioblastomas almost invariably progress or recur after a median of 4-8 months. The strategy to repeat tumor resection at recurrence in order to minimize tu…
Phase 2 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Experimental gene therapy targets rare nerve disease
Disease control CompletedTitle: Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy Background: \- The Gigaxonin gene lets the body make a protein chemical called Gigaxonin. Nerves need Gigaxonin to work properly. Giant Axonal Neuropathy (GAN) causes a shortage of …
Phase 1 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a smartphone camera spot blinding eye diseases?
Diagnosis CompletedTo validate new screening instruments for eye disease, increase eye care access in underserved communities, and provide a scientifically implemented method to set up programs for eye disease screening.
Sponsor: University of Michigan • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
New drug combo aims to keep myeloma in check after transplant
Disease control OngoingThis phase II trial studies how well elotuzumab works when given with lenalidomide as maintenance therapy after transplant in patients with newly diagnosed multiple myeloma who underwent transplant using their own stem cells (autologous transplant). Maintenance therapy is treatme…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Testicular cancer trial: could a stronger chemo course cut relapse risk?
Disease control OngoingOne course of adjuvant carboplatin AUC7 is considered internationally to be a standard treatment option in clinical stage I seminoma, regardless of risk factors. Treatment is based on a large, randomized phase III study comparing adjuvant carboplatin with adjuvant radiotherapy. T…
Phase 3 • Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Ketamine shows promise for rapid relief of suicidal ideation
Symptom relief CompletedThe primary objective of this study is to assess the efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS hetero questionnaire, in patients hospitalized for suicide risk.
Phase 3 • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
New chemo combo may lower death risk in child stem cell transplants
Disease control CompletedThe aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v. Busulfan, each administered as part of a standardised Fludarabine-containing conditioning regimen and to contribute to a PK model…
Phase 2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy after transplant shows promise for tough lymphomas
Disease control CompletedThis phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New heart valve procedure offers hope for High-Risk patients
Disease control OngoingPILOT: The study is a pilot trial to evaluate the safety and performance of the Twelve TMVR System in high risk mitral regurgitation patients. EFS: The study is an Early Feasibility Study to evaluate the safety and performance of the Medtronic Intrepid™ Transcatheter Mitral Va…
Sponsor: Medtronic Cardiovascular • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Stem cells injected into eye aim to halt blindness
Disease control OngoingThe main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, an…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Immune booster shows promise against rare cancer
Disease control CompletedThis phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell de…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can extra rituximab keep vasculitis at bay?
Disease control CompletedMAINRITSAN study compared Rituximab and azathioprine as maintenance therapy for ANCA-associated vasculitides. In this study, Rituximab (5 infusions at D1, D15, M6, M12, M18) was superior to azathioprine (2 mg/kg/day) to prevent relapses of AAV 28 months after the inclusion (Guill…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo therapy aims to halt returning prostate cancer
Disease control CompletedThe primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to standard-of-care salvage radiation therapy to allow for furthe…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy combo shows promise in reducing head and neck cancer recurrence
Disease control CompletedThe goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surg…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat their cancer. In these transplants, chemotherapy and …
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kids with tough cancers: immunotherapy drug tested
Disease control Recruiting nowResearchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means c…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for tough lymphoma: targeted drug shows promise in Mid-Stage trial
Disease control OngoingThe purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
Phase 2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a common blood thinner stop silent heart attacks?
Disease control CompletedHeart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely explain the development of narrowing within the heart …
Phase 2/3 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC